| HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells E Carbone, P Neri, M Mesuraca, MT Fulciniti, T Otsuki, D Pende, V Groh, ... Blood 105 (1), 251-258, 2005 | 416 | 2005 |
| Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells L Catley, E Weisberg, T Kiziltepe, YT Tai, T Hideshima, P Neri, P Tassone, ... Blood 108 (10), 3441-3449, 2006 | 402 | 2006 |
| Dysfunctional T regulatory cells in multiple myeloma RH Prabhala, P Neri, JE Bae, P Tassone, MA Shammas, CK Allam, ... Blood 107 (1), 301-304, 2006 | 290 | 2006 |
| Role of B-cell–activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment YT Tai, XF Li, I Breitkreutz, W Song, P Neri, L Catley, K Podar, ... Cancer research 66 (13), 6675-6682, 2006 | 279 | 2006 |
| A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells D Chauhan, G Li, K Podar, T Hideshima, P Neri, D He, N Mitsiades, ... Cancer research 65 (18), 8350-8358, 2005 | 212 | 2005 |
| Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications MA Shammas, P Neri, H Koley, RB Batchu, RC Bertheau, V Munshi, ... Blood 108 (8), 2804-2810, 2006 | 200 | 2006 |
| Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM) D Chauhan, P Neri, M Velankar, K Podar, T Hideshima, M Fulciniti, ... Blood 109 (3), 1220-1227, 2007 | 184 | 2007 |
| Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138+ multiple myeloma cells P Tassone, VS Goldmacher, P Neri, A Gozzini, MA Shammas, ... Blood 104 (12), 3688-3696, 2004 | 182 | 2004 |
| Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion P Neri, L Ren, AK Azab, M Brentnall, K Gratton, AC Klimowicz, C Lin, ... Blood, The Journal of the American Society of Hematology 117 (23), 6202-6213, 2011 | 168 | 2011 |
| A clinically relevant SCID-hu in vivo model of human multiple myeloma P Tassone, P Neri, DR Carrasco, R Burger, VS Goldmacher, R Fram, ... Blood 106 (2), 713-716, 2005 | 163 | 2005 |
| MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo T Hideshima, P Neri, P Tassone, H Yasui, K Ishitsuka, N Raje, D Chauhan, ... Clinical cancer research 12 (19), 5887-5894, 2006 | 159 | 2006 |
| Neutralizing B-cell–activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model P Neri, S Kumar, MT Fulciniti, S Vallet, S Chhetri, S Mukherjee, YT Tai, ... Clinical Cancer Research 13 (19), 5903-5909, 2007 | 158 | 2007 |
| Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors P Neri, L Ren, K Gratton, E Stebner, J Johnson, A Klimowicz, P Duggan, ... Blood, The Journal of the American Society of Hematology 118 (24), 6368-6379, 2011 | 156 | 2011 |
| Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma NJ Bahlis, H Sutherland, D White, M Sebag, S Lentzsch, R Kotb, ... Blood, The Journal of the American Society of Hematology 132 (24), 2546-2554, 2018 | 150 | 2018 |
| Multiple myeloma immunoglobulin lambda translocations portend poor prognosis BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, ... Nature communications 10 (1), 1911, 2019 | 138 | 2019 |
| Validation of PDGFRβ and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib AML Coluccia, T Cirulli, P Neri, D Mangieri, MC Colanardi, A Gnoni, ... Blood, The Journal of the American Society of Hematology 112 (4), 1346-1356, 2008 | 128 | 2008 |
| A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells T Calimeri, E Battista, F Conforti, P Neri, MT Di Martino, M Rossi, ... Leukemia 25 (4), 707-711, 2011 | 126 | 2011 |
| Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo MA Shammas, H Koley, RC Bertheau, P Neri, M Fulciniti, P Tassone, ... Leukemia 22 (7), 1410-1418, 2008 | 125 | 2008 |
| Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo P Tassone, MT Di Martino, M Ventura, A Pietragalla, I Cucinotto, ... Cancer biology & therapy 8 (7), 648-653, 2009 | 122 | 2009 |
| Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of … P Tassone, P Neri, R Burger, R Savino, M Shammas, L Catley, K Podar, ... Clinical cancer research 11 (11), 4251-4258, 2005 | 109 | 2005 |
